LYNCH Biologics Closes on Transaction to Purchase GEM 21S® Growth Factor Enhanced Matrix for Dental Bone Regeneration

Register to receive a free US Market Report Suite for Dental Bone Graft Substitutes and Other Biomaterials report synopsis and brochure

LYNCH Biologics LLC (LBIO) announced that it has closed on a transaction with Luitpold Pharmaceuticals Inc. (LPI), under which LBIO hasacquired all rights relating to GEM 21S Growth Factor Enhance Matrix, and certain additional assets related to LPI’s dental regeneration business.  The transaction transfers all ownership rights to LBIO for the global commercialization of GEM 21S, including the downstream formulation, fill and finish manufacturing rights. LYNCH Biologics will market the GEM 21S product together with a suite of complementary regenerative biologic products direct to oral surgeons, periodontists and implant dentists through its cranio-maxillofacial division. The terms of the transaction were not disclosed.

About LYNCH Biologics LLC

Lynch Biologics (“LBIO” or “the Company”), is a biotechnology company focused on regenerative medicine, using special bioactive proteins to give healthcare providers treatment options for patients who are experiencing a variety of demanding healing challenges, from diabetic foot ulcers to major dental surgeries and everything in between… quite literally from head to toe. This mission is being achieved through commercialization of innovative biologics, biomaterials and cell therapies acquired via M&A, licensing and internal R&D. Commercialization is through a direct sales force in the U.S. and licensing partners worldwide. The Company currently has four areas of focus, improving healing of wounds such as diabetic foot ulcers and post-surgical wound complications, dental/craniofacial bone and soft tissue regeneration, supplying of protein growth factors used in the manufacturing of mesenchymal stem cell therapies and globalization of its businesses. Dr. Sam Lynch, LBIO founder and CEO, is the founder and former CEO of BioMimetic Therapeutics, Inc. He is the inventor of the technology and led the team that successfully achieved marketing approval in the U.S. and internationally for GEM 21S and Augment Bone Graft.

About Luitpold Pharmaceuticals, Inc.

Luitpold Pharmaceuticals, Inc. is a group company of Daiichi Sankyo Co., Ltd. of Japan. Since 1994, Luitpold has been proudly marketing bone grafting and tissue regeneration products used by dental professionals throughout the world through its Osteohealth division. The company’s overriding goal is to develop and distribute, with professionalism and integrity, products of the highest quality that have been scientifically and clinically proven to enhance patient care.


For Further Information

More on the dental bone graft substitute market in the U.S. can be found in a series of reports published by iData Research entitled the U.S. Market Report Suite for Dental Bone Graft Substitutes and Other Biomaterials. The suite covers reports on the following markets: dental bone graft substitutes, dental growth factors and dental barrier membranes.

The iData report series on dental bone graft substitutes covers the U.S., Latin America (Argentina, Brazil, Mexico) and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more about dental bone graft substitutes market data, register online or email us at for a U.S. Market Report Suite for Dental Bone Graft Substitutes and Other Biomaterials brochure and synopsis.

Leave a Reply